[{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Raziel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Raziel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Raziel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Raziel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raziel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Undisclosed","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raziel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for RZL-012

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : RZL-012 is an injectable lipolytic drug, works by destroys fat cells and reduces fat volume, currently being developed for the reduction of unwanted submental fat in adults

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 03, 2025

                          Lead Product(s) : RZL-012

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 10, 2023

                          Lead Product(s) : RZL-012

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 27, 2022

                          Lead Product(s) : RZL-012

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 20, 2022

                          Lead Product(s) : RZL-012

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 06, 2022

                          Lead Product(s) : RZL-012

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 30, 2021

                          Lead Product(s) : RZL-012

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 14, 2020

                          Lead Product(s) : RZL-012

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 12, 2019

                          Lead Product(s) : RZL-012

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 10, 2018

                          Lead Product(s) : RZL-012

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : University of Arizona

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 31, 2017

                          Lead Product(s) : RZL-012

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Spaulding Clinical, LLC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank